Equillium Inc
NASDAQ:EQ
Equillium Inc
Other Current Liabilities
Equillium Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Other Current Liabilities
$2.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Liabilities
$1.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
41%
|
CAGR 10-Years
21%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Liabilities
$363m
|
CAGR 3-Years
11%
|
CAGR 5-Years
32%
|
CAGR 10-Years
32%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Liabilities
$627.7m
|
CAGR 3-Years
12%
|
CAGR 5-Years
1%
|
CAGR 10-Years
14%
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Other Current Liabilities?
Other Current Liabilities
2.1m
USD
Based on the financial report for Sep 30, 2024, Equillium Inc's Other Current Liabilities amounts to 2.1m USD.
What is Equillium Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 1Y
-87%
Over the last year, the Other Current Liabilities growth was -87%.
You don't have any saved screeners yet